Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) priced a best-efforts public offering of 21,000,000 common shares and accompanying warrants at a combined price of $0.50 per unit, with aggregate gross proceeds of approximately $10.5 million.

Warrants carry a $0.68 exercise price, are exercisable on issuance, and expire at the earlier of five years or 180 days after public release of first-cohort Phase 1 ERNA-101 clinical data. Closing expected on or about February 10, 2026. Proceeds intended for program advancement, working capital, and general corporate purposes.

Positive

• Aggregate gross proceeds of $10.5 million
• Potential additional cash of $14.3 million if warrants fully exercised
• Proceeds earmarked to advance development programs and provide working capital

Negative

• Issuance of 21,000,000 shares plus warrants could cause meaningful dilution
• Offering price of $0.50 per unit is low relative to typical secondary raises
• Warrants expire earlier if Phase 1 ERNA-101 first-cohort data is publicly released, adding exercise timing uncertainty

News Market Reaction – ERNA

-44.66% 3.8x vol

32 alerts

-44.66% News Effect

-42.9% Trough in 3 hr 22 min

-$4M Valuation Impact

$5M Market Cap

3.8x Rel. Volume

On the day this news was published, ERNA declined 44.66%, reflecting a significant negative market reaction. Argus tracked a trough of -42.9% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $5M at that time. Trading volume was very high at 3.8x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Shares offered: 21,000,000 shares Warrants offered: 21,000,000 warrants Offering price: $0.50 per share + warrant +3 more

6 metrics

Shares offered 21,000,000 shares Common stock (or equivalents) in best-efforts public offering

Warrants offered 21,000,000 warrants Warrants to purchase common stock issued with the shares

Offering price $0.50 per share + warrant Combined public offering price for each share and accompanying warrant

Warrant exercise price $0.68 per share Exercise price of warrants issued in the offering

Gross proceeds $10.5 million Expected aggregate gross proceeds before fees and expenses

Potential warrant proceeds $14.3 million Potential additional gross proceeds if all warrants exercised for cash

Market Reality Check

Price: $0.2703 Vol: Volume 155,754 is at 0.78...

normal vol

$0.2703 Last Close

Volume Volume 155,754 is at 0.78x its 20-day average of 198,931. normal

Technical Price at 0.68 trades below 200-day MA of 1.78 and close to 52-week low 0.6701.

Peers on Argus

ERNA is down 19.76% with sector peers mostly weaker (BOLT -2.18%, CELZ -6.41%, I...

1 Down

ERNA is down 19.76% with sector peers mostly weaker (BOLT -2.18%, CELZ -6.41%, INTS -3.53%, KZIA -4.91%), while MBIO shows a large gain of 16.75%. Momentum scanner only flags MBIO moving down separately, reinforcing a stock-specific reaction tied to ERNA’s offering.

Historical Context

5 past events · Latest: Feb 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 03	FDA meeting update	Positive	-25.8%	Virtual investor segment on successful Pre-IND FDA meeting for ERNA-101.
Jan 27	Program selection	Positive	-0.8%	Selection for JETRO Japan Entry Acceleration Program to support pipeline.
Jan 06	Regulatory progress	Positive	+5.0%	Successful Pre-IND FDA meeting and path toward first-in-human trial.
Dec 08	Preclinical data	Positive	-1.5%	Presentation of ERNA-101 preclinical data showing immune reprogramming effects.
Dec 03	Conference presentation	Positive	-4.2%	Announcement of upcoming ASH oral presentation on iMSC platform data.

Pattern Detected

Recent positive clinical and strategic updates were often followed by negative price reactions, suggesting a pattern of selling into good news.

Recent Company History

Over the last few months, Ernexa highlighted progress for lead cell therapy ERNA-101, including successful Pre-IND FDA meetings and plans for a first-in-human ovarian cancer trial in H2 2026. The company also showcased preclinical data at the ASH meeting and joined JETRO’s Japan Entry Acceleration Program. Despite mostly constructive catalysts, shares often moved lower after news, indicating investor focus on financing needs and risk disclosures ahead of today’s $10.5 million offering.

Market Pulse Summary

The stock dropped -44.7% in the session following this news. The decline reflects dilution concerns ...

Analysis

The stock dropped -44.7% in the session following this news. The decline reflects dilution concerns from issuing 21,000,000 shares and 21,000,000 warrants at a combined $0.50, versus a pre-news price near $0.68. This fits a pattern where ERNA often traded lower after ostensibly positive updates, with four of the last five news events followed by negative moves. With shares already 87.74% below the 52-week high and near the 0.6701 low, reactions may remain sensitive to further capital-raising needs.

Key Terms

best-efforts registered public offering, warrants, exercise price, phase 1 study, +2 more

6 terms

best-efforts registered public offering financial

"announced the pricing of a best-efforts registered public offering of 21,000,000"

A best-efforts registered public offering is a way a company sells new shares to the public with a securities registration in place while the broker-dealer agrees to try to sell as many shares as possible but does not promise to buy any unsold portion. Think of the broker as a salesperson who will attempt to find buyers but can return leftovers to the company; investors should note this raises uncertainty about how many shares will actually trade, potential price impact, and how much money the company will receive.

warrants financial

"and warrants to purchase up to 21,000,000 shares of common stock, at a"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"The warrants will have an exercise price of $0.68 per share, will be"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

phase 1 study medical

"clinical trial data from the first cohort of the Phase 1 study of ERNA-101."

A phase 1 study is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, side effects and the right dose rather than proving effectiveness. Think of it as a short, closely monitored test drive that checks how the body tolerates the treatment and how it behaves inside the body; results matter to investors because positive safety and dosing data are needed before larger, more value-driving trials can begin.

registration statement on form s-1 regulatory

"pursuant to a registration statement on Form S-1 (File No. 333-293150),"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering is being made only by means of a prospectus forming part of the"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equivalent in lieu thereof) and accompanying warrant.

The warrants will have an exercise price of $0.68 per share, will be exercisable upon issuance, and will expire on the earlier to occur of (i) the five-year anniversary of the initial issuance date, or (ii) the 180^th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. The closing of the offering is expected to occur on or about February 10, 2026, subject to the satisfaction of customary closing conditions.

Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as the exclusive placement agent for the offering.

Ernexa intends to use the net proceeds from the offering to support the advancement of its development programs, working capital, and general corporate purposes.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $10.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the exercise of the warrants, if fully exercised on a cash basis, would be approximately $14.3 million. No assurance can be given that any warrants will be exercised.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-293150), as amended, which was declared effective by the Securities and Exchange Commission (the “SEC”) on February 5, 2026. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov and a final prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained, when available, by contacting Brookline Capital Markets, a division of Arcadia Securities, LLC at 600 Lexington Avenue, 30th Floor, New York, New York 10022, by phone at (646) 603-6716.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the Company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The Company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

FAQ

What did Ernexa (ERNA) announce in the February 6, 2026 public offering?

Ernexa announced a best-efforts offering of 21,000,000 shares plus warrants at $0.50 per unit. According to the company, aggregate gross proceeds are expected to be about $10.5 million before fees, with potential additional proceeds of roughly $14.3 million if warrants are fully exercised.

What are the key warrant terms in Ernexa's (ERNA) offering?

Warrants accompany each unit with a $0.68 exercise price and are exercisable upon issuance. According to the company, warrants expire on the earlier of five years or 180 days after public release of first-cohort Phase 1 ERNA-101 clinical data.

When is the expected closing date for Ernexa's (ERNA) offering and what conditions apply?

The closing is expected on or about February 10, 2026, subject to customary closing conditions. According to the company, the offering is being conducted on a best-efforts basis with Brookline Capital Markets as exclusive placement agent.

How does the offering affect Ernexa (ERNA) shareholders and dilution risk?

The offering could dilute existing holders since 21,000,000 new shares and 21,000,000 warrants are being issued. According to the company, the shares and warrants are being sold to raise capital to advance development programs and support working capital.

Where can investors find the prospectus and registration information for Ernexa's (ERNA) offering?

A registration statement on Form S-1 was declared effective by the SEC on February 5, 2026, and a prospectus is available on the SEC website. According to the company, electronic copies of the final prospectus will be available on the SEC site and from Brookline Capital Markets when filed.